University College London Hospitals (UCLH) researchers used a light-sensitive drug, which is injected into the bloodstream. A laser then activates the drug, which eradicates tumor tissue in the prostate. This new treatment is called vascular-targeted photodynamic therapy, or VTP.
Published in The Lancet Oncology, the study showed that 49 percent of patients given VTP went into ‘complete remission’ compared with 13.5 percent of patients in the control group.
The scientific title of the study is called 'Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial'
Read more on CNBC's website:
www.cnbc.com/2016/12/20/a-new-form-of-therapy-involving-lasers-could-transform-the-way-prostate-cancer-is-treated.html
Read the scientific article on The Lancet Oncology's website:
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30661-1/fulltext
The scientific title of the study is called 'Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial'
Read more on CNBC's website:
www.cnbc.com/2016/12/20/a-new-form-of-therapy-involving-lasers-could-transform-the-way-prostate-cancer-is-treated.html
Read the scientific article on The Lancet Oncology's website:
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30661-1/fulltext
